Kura Oncology Inc (KURA) Shares Bought by Partner Fund Management L.P.

Partner Fund Management L.P. grew its holdings in Kura Oncology Inc (NASDAQ:KURA) by 1.5% during the 3rd quarter, Holdings Channel reports. The firm owned 1,103,656 shares of the company’s stock after acquiring an additional 16,533 shares during the quarter. Partner Fund Management L.P.’s holdings in Kura Oncology were worth $19,314,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the company. Allianz Asset Management GmbH acquired a new stake in shares of Kura Oncology in the third quarter valued at about $1,661,000. Carillon Tower Advisers Inc. grew its position in shares of Kura Oncology by 62.2% in the third quarter. Carillon Tower Advisers Inc. now owns 1,502,217 shares of the company’s stock valued at $26,288,000 after purchasing an additional 576,221 shares during the last quarter. Credit Suisse AG grew its position in shares of Kura Oncology by 36.7% in the third quarter. Credit Suisse AG now owns 18,142 shares of the company’s stock valued at $318,000 after purchasing an additional 4,869 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Kura Oncology in the third quarter valued at about $217,000. Finally, BlackRock Inc. grew its position in shares of Kura Oncology by 19.7% in the third quarter. BlackRock Inc. now owns 2,396,137 shares of the company’s stock valued at $41,932,000 after purchasing an additional 393,872 shares during the last quarter. 79.28% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on KURA shares. BidaskClub downgraded Kura Oncology from a “buy” rating to a “hold” rating in a research report on Thursday, August 9th. Zacks Investment Research downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, October 10th. ValuEngine downgraded Kura Oncology from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 19th. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price target on shares of Kura Oncology in a research report on Monday, October 22nd. Finally, Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Monday, October 22nd. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Kura Oncology has an average rating of “Buy” and a consensus target price of $26.86.

KURA stock opened at $12.86 on Thursday. Kura Oncology Inc has a twelve month low of $10.20 and a twelve month high of $24.02. The stock has a market cap of $497.52 million, a P/E ratio of -8.61 and a beta of 4.41. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.76 and a current ratio of 14.76.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Monday, November 5th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.01. On average, sell-side analysts predict that Kura Oncology Inc will post -1.72 earnings per share for the current fiscal year.

WARNING: This news story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/12/06/kura-oncology-inc-kura-shares-bought-by-partner-fund-management-l-p.html.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Recommended Story: Liquidity

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology Inc (NASDAQ:KURA).

Institutional Ownership by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply